ACA
OCUL icon

Avoro Capital Advisors’s Ocular Therapeutix OCUL Stock Holding History

Avoro Capital Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104M Buy
12,315,000
+1,537,223
+14% +$14.7M 1.03% 17
2025
Q4 		$131M Buy
10,777,777
+527,777
+5% +$6.41M 1.29% 20
2025
Q3 		$120M Buy
10,250,000
+2,850,000
+39% +$34.1M 1.55% 19
2025
Q2 		$68.7M Sell
7,400,000
-660,000
-8% -$5.17M 1.2% 18
2025
Q1 		$59.1M Hold
8,060,000
– – 0.92% 21
2024
Q4 		$68.8M Hold
8,060,000
– – 0.97% 23
2024
Q3 		$70.1M Hold
8,060,000
– – 1.02% 21
2024
Q2 		$55.1M Buy
8,060,000
+911,064
+13% +$5.62M 0.73% 26
2024
Q1 		$65.1M Buy
+7,148,936
New +$50.7M 0.76% 29

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return